Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Document › Details

Miltenyi Biotec GmbH. (8/14/14). "Press Release: Miltenyi Biotec Acquires Gene Therapy Assets from Lentigen Corporation". Bergisch Gladbach.

Organisations Organisation Lentigen Corporation
  Today Opus Bio Inc.
  Group Opus Bio Inc.
  Organisation 2 Lentigen Technology Inc. (LTI)
  Group Miltenyi Biotec (Group)
Products Product lentiviral vector
  Product 2 gene therapy
Index terms Index term Lentigen–Miltenyi Biotec: investment, 201408 acquisition lentiviral manufacturing business + assets continuing as Miltenyi sub Lentigen Technology Inc
  Index term 2 Miltenyi Biotec–Scott Partnership: public relations, 201308 service existent by Phoenix MarCom
Persons Person Miltenyi, Stefan (Miltenyi Biotec 201404 Founder + President)
  Person 2 England, Claire (Scott Partnership 201408 at Phoenix MarCom)
     


Addition of lentiviral gene delivery capabilities complements strategic partnering portfolio.


Miltenyi Biotec announced today that it has acquired the lentiviral vector manufacturing business and related assets from US company Lentigen Corporation, a global leader in lentiviral technology for cell and gene therapy applications.

The acquisition further strengthens Miltenyi Biotec's portfolio in cell and gene therapy. Assets obtained in the transaction include a broad range of intellectual property, process technologies, and cGMP-qualified manufacturing facilities. The Lentigen team will join Miltenyi Biotec, and operate through its newly formed, wholly owned US subsidiary Lentigen Technology, Inc. based in Gaithersburg, MD.

Miltenyi Biotec will leverage the combined capabilities by offering customized system and application design in strategic partnerships with clinical investigators and companies to develop and commercialize cell and gene therapies.

"It is our goal at Miltenyi Biotec to become the major supplier of lentiviral vectors for cell and gene therapies, both for clinical research and at commercial scale," said Stefan Miltenyi, Chief Executive Officer of Miltenyi Biotec. "With the acquisition of the Lentigen assets, we have strengthened our comprehensive portfolio that will enable our current and future partners to proceed in cell therapies efficiently from preclinical testing through human studies to automated manufacturing for widespread commercial therapeutic use, all with a single strategic partner."

Lentiviral technology provides the most efficient method for delivering genetic material into cells to modulate their function, as demonstrated by recent clinical trials in genetic diseases and oncology indications utilizing lentivirus-modified chimeric antigen receptor (CAR) T cells.

Concurrent with the transaction, the sellers, now operating as Opus Bio, Inc., have been granted certain rights to deploy lentiviral technology in some therapeutic indications, for which Lentigen Technology, Inc. shall be the preferred manufacturing supplier.


About Miltenyi Biotec

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company's integrated tools support research at every level, from basic research to translational research to clinical application. Their technologies cover techniques of sample preparation, cell isolation, flow sorting, flow cytometry, cell culture, molecular analysis, and preclinical imaging. The company's more than 25 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer, and clinical research areas like hematology, graft engineering, and apheresis. Trusted around the world, the Miltenyi Biotec brand continues to set new standards in the industry. Miltenyi Biotec has more than 1,400 employees in 25 countries.


Media Contact:

Claire England
Tel: +44 (0)1480 471045
claire.england@phoenixmarcom.co.uk

   
Record changed: 2017-04-02

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Partnering 600x60px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Biotech Showcase 2019 BTS San Francisco Investors 600x60px




» top